Evidence map›Paper›PMID 28399558›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2017

Brief Report: Hormonal Contraception Is Not Associated With Reduced ART Effectiveness Among Women Initiating ART: Evidence From Longitudinal Data.

Rena C Patel, Jared M Baeten, Renee Heffron, Ting Hong, Nicole L Davis, Kavita Nanda, Robert W Coombs, Jairam R Lingappa, Elizabeth A Bukusi, Stacey Hurst and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. A practical clinical guide to counselling on and managing contraception, pre-conception planning, and menopause for women living with HIV.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2021
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Rena C PatelDepartments of *Medicine;†Global Health;‡Epidemiology, University of Washington, Seattle, WA;§Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA;‖FHI 360, Integrated Health Sciences, Research Triangle Park, NC;¶Department of Obstetrics and Gynecology, University of Washington, Seattle, WA;#Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya; and**Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.
Jared M Baeten
Renee Heffron
Ting Hong
Nicole L Davis
Kavita Nanda
Robert W Coombs
Jairam R Lingappa
Elizabeth A Bukusi
Stacey Hurst
Katherine K Thomas
Athena P Kourtis
Nelly Mugo
Partners in Prevention HSVHIV Transmission Study and Partners PrEP Study Teams
University of Washington · USKenya Medical Research Institute · KENational Center for Chronic Disease Prevention and Health Promotion · USCenters for Disease Control and Prevention · USTriangle · US

Funding

Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
Viral Determinants of HIV-1 Transmission in African HeterosexualsP01AI057005 · NIAID · UNIVERSITY OF WASHINGTON · PI LINGAPPA, JAIRAM RAO · 2003 to 2014
$20.5M
Investigating interactions between efavirenz-based antiretroviral therapy and contraceptive implantsK23AI120855 · NIAID · UNIVERSITY OF WASHINGTON · PI PATEL, RENA CHIMAN · 2015 to 2019
$850k
Hormonal contraception, pre-exposure prophylaxis, and HIV-1 protectionR21HD074439 · NICHD · UNIVERSITY OF WASHINGTON · PI BAETEN, JARED · 2013 to 2014
$432k
NIAID NIH HHS K23 AI120855NIAID NIH HHS P01 AI057005NIAID NIH HHS P30 AI027757NIAID NIH HHS UM1 AI106701NICHD NIH HHS R21 HD074439
6 · The paper itself

Abstract

backgroundTo explore the association between concomitant hormonal contraceptive and antiretroviral therapy (ART) use and (1) plasma viral suppression and (2) genital HIV shedding among HIV-positive women initiating ART.

methodsWe analyzed plasma viral load and genital viral RNA shedding from 1079 HIV-positive women initiating ART who were followed prospectively in 3 sub-Saharan African HIV prevention studies. Plasma and endocervical swab samples were collected every 6 months. Self-reported contraceptive use was categorized into injectable, implant, oral, or nonhormonal/no contraception. We used multivariate Cox regression to assess time to plasma viral suppression and logistic regression with generalized estimating equations to assess genital viral shedding for each contraceptive method.

resultsAt the time of ART initiation, there were 211 (20%) injectable, 69 (6%) implant, 50 (5%) oral, and 749 (69%) nonhormonal or no method users. Plasma viral suppression was high (90% by 6 months) and hormonal contraceptives did not diminish time to plasma viral suppression as compared to nonhormonal/no methods [adjusted hazard ratios: injectables 0.89 (95% confidence interval: 0.75 to 1.07), implants 0.91 (0.68 to 1.23), and oral methods 1.33 (1.06 to 1.66)]. Genital viral shedding was uncommon any time after ART initiation (only 9% of samples had detectable viral shedding) and hormonal contraceptives were not associated with an increased detection of genital viral shedding [adjusted odds ratios: injectables 1.07 (0.69 to 1.65), implants 0.67 (0.31 to 1.49), and oral methods 0.56 (0.19 to 1.69)].

conclusionsThe hormonal contraceptives assessed were not associated with reduced ART effectiveness among HIV-positive women initiating ART. HIV-positive women should continue to be offered contraceptive options, including hormonal ones that best meet their needs.

Indexed as

Drug InteractionsHIVViral LoadVirus SheddingAdultAfrica South of the SaharaAnti-Retroviral AgentsCervix UteriContraceptives, Oral, HormonalFemaleHIV InfectionsHumansLongitudinal StudiesRNA, ViralTreatment OutcomeAnti-Retroviral AgentsContraceptives, Oral, HormonalRNA, Viral

Identifiers

PMID28399558
PMCPMC5407405
OpenAlexW2592986257

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.